S.B. 2592 Summary

• Defines "clinical laboratory director" to include physicians, advanced practice registered nurses, licensed clinical laboratory scientists, and pharmacists (for waived tests only).

• Expands pharmacist scope of practice to allow ordering and performing Clinical Laboratory Improvement Amendments (CLIA)-waived tests, including FDA-approved or FDA-authorized tests classified as waived.

• Permits pharmacists to perform waived tests with appropriate training from ACPE-approved programs, college of pharmacy curricula, or health department programs.

• Excludes tests requiring vaginal swab, venipuncture, or seminal fluid collection from pharmacist performance authority.

• Effective January 1, 2050.